Home > Back to Publisher > Report Information

MarketVIEW: Lyme borreliosis vaccines (CAT No: VAMV024)

VacZine Analytics
October 1, 2010
85 Pages - SKU: VZAN6066477

Abstract Table of Contents Related Reports

Lyme Borreliosis (LB) or Lyme disease is caused by an infection with the bacterial spirochete Borrelia genospecies. The pathogen is transmitted to humans through the bite of infected Ixodes tick species. LB, which is endemic is large areas of Europe and North America, can cause a wide range of disease symptoms which range from a mild treatable rash to serious complications of the neurological system (neuroborreliosis). The incidence of LB in the US has tripled in the last 15 years and is also significant in continental Europe. GSK Biologicals licensed a recombinant vaccine (LYMErix) in 1998 which was later withdrawn due to a number of reasons.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new Lyme Borreliosis vaccines across endemic markets to 2030. The model contains value ($ m) and volume (mio doses) predictions for each country and discusses current dynamics in disease incidence with comprehensive epidemiological reviews and risk maps. The analysis also covers a GSK LYMErix case study, cost effectiveness and new LB vaccine target product profiles. It is essential reading for any organisation wishing to reconsider the development of new LB vaccines.

Please Note: this is delivered as a Zip file.

Summary presentation (MS PowerPoint based): Author’s note; Executive Summary; Lyme Borreliosis vaccines: available market EU+US ($ 000s) to 2030; Lyme Borreliosis vaccines: predicted demand EU+US (Doses 000s) to 2030; Lyme Borreliosis vaccines: available US market ($ 000s) to 2030; Lyme Borreliosis vaccines: available EU market ($ 000s) to 2030; Lyme Borreliosis: latest disease trends and dynamics; Lyme Borreliosis: background; Clinical features; Age distribution; Distribution of genospecies; Epidemiology - US; Epidemiology - EU; Lyme Borreliosis: key model assumptions; Background to Lyme Borreliosis vaccines; Lyme Borreliosis vaccines: GSK’s LYMErix; Cost effectiveness of Lyme disease vaccination; Lyme Borreliosis vaccines: target product profiles; Vaccine target populations; Estimated vaccine uptake; Major commercial model assumptions; Commercial model assumptions by country; Vaccine pipeline; Appendix I - Lyme borreliosis: focused country overview; Austria; Belgium; Croatia; Czech Republic; Finland; France; Germany; Hungary; Italy; The Netherlands; Poland; Slovakia; Slovenia; Sweden; Switzerland; Other countries; Appendix II - Lyme borreliosis: country risk maps; US risk areas; Belgium risk areas; Croatia risk areas; France risk areas; Germany risk areas; Hungary risk areas; Finland risk areas; Bibliography; About VacZine Analytics; Disclaimer
PAGES: 80 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents - Vaccine demand model (MS Excel-based): Title sheet; Total charts; Charts value; Charts volume; Value summary (TOTAL MARKET); Volume summary (TOTAL MARKET); US (base) adult; US (base) infant; Austria (base) adult; Austria (base) infant; Belgium (base) adult; Belgium (base) infant; Croatia (base) adult; Croatia (base) infant; Czech (base) adult; Czech (base) infant; Finland (base) adult; Finland (base) infant; France (base) adult; France (base) infant; Germany (base) adult; Germany (base) infant; Hungary (base) adult; Hungary (base) infant; Holland (base) adult; Holland (base) infant; Poland (base) adult; Poland (base) infant; Slovakia (base) adult; Slovakia (base) infant; Slovenia (base) adult; Slovenia (base) infant; Sweden (base) adult; Sweden (base) infant; Switzerland (base) adult; Switzerland (base) infant; Source material; Incidence rates (US); Incidence rates (EU); Populations at risk; Genospecies
WORKSHEETS:: ****This product is composed of a model and summary presentation

MarketVIEW: Lyme borreliosis vaccines (CAT No: VAMV024)

Share this report

Other tasks

Research Assistance

Related Markets

Vaccines Reports

Free Alert Me service